GILEAD SCIENCES WINS DELAWARE JURY TRIAL DEFEATING BILLION-DOLLAR US GOVERNMENT LAWSUIT OVER HIV PREVENTION DRUG PATENTS -GILEAD STATEMENT . | May 9, 2023
Gilead Sciences, Inc. is currently at $79.24, down $0.21 or 0.26% Would be lowest close since March 23, 2023, when it closed at $78.76 Currently down eight consecutive days;. | May 4, 2023
Gilead Sciences Inc is headed
to trial in Delaware federal court this week to fight claims
that it owes the U.S. government a share of multibillion-dollar
profits from its HIV-prevention drug. | May 2, 2023
Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conferences:
BofA Securities Health Care Conference on Tuesday, May 9 at 2:20pm ET
RBC. | May 1, 2023
Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated.. | April 27, 2023